Harold Varmus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harold Varmus has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Eric Edison Gardner
Meyer Cancer Center, Weill Cornell Medicine
50 shared publications - Lewis Clayton Cantley
Department of Cell Biology, Harvard Medical School, Boston, USA
48 shared publications - Benjamin D. Stein
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
47 shared publications - John R. Ferrarone
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
46 shared publications - Chen Zhang
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
45 shared publications - David Wu
Sandra and Edward Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, New York
45 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S2. Phosphorylation of human TPI1 is LKB1-dependent.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S1. Differential co-occurrence and effects of KRAS, TP53 and LKB1 mutations on human and mouse LUADs.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S5. LKB1 regulates the multimeric state of hTPI1 but not mTpi1 and substitution of Cys in hTPI1 causes formation of a covalent TPI1 dimer.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S3. TPI1 phosphorylation regulates triose phosphate levels and metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S6. TPI1 allelic variants effects central carbon metabolic flux.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S4. Members of the salt Inducible kinase family phosphorylate TPI1.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S8. Tpi1 inactivation in KL autochthonous tumor model alters histology and pathology.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Figure S7. Tpi1 is required for tumor growth in KP and KPL LUAD models.
- Open Access
- 22 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs
We previously described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here, we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant MYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of MYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA-sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.
- 22 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessMetastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs
We previously described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here, we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant MYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of MYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA-sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.
- Open Access
- 3 January 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Formation of malignant, metastatic small cell lung cancers through overproduction of cMYC protein in TP53 and RB1 depleted pulmonary neuroendocrine cells derived from human embryonic stem cells
We recently described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant cMYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of cMYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.
- 3 January 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessFormation of malignant, metastatic small cell lung cancers through overproduction of cMYC protein in TP53 and RB1 depleted pulmonary neuroendocrine cells derived from human embryonic stem cells
We recently described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant cMYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of cMYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.